EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The engineered exosomes targeting ferroptosis: A novel approach to reverse immune checkpoint inhibitors resistance

Anqi Chen iD, Wenjie Zhang, Chuwen Jiang, Zhengting Jiang iD, Dong Tang

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34934 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Anqi Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, Yangzhou University, Yangzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Exosomes, Ferroptosis, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 106 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have been extensively used in immunological therapy primarily due to their ability to prolong patient survival. Although ICIs have achieved success in cancer treatment, the resistance of ICIs should not be overlooked. Ferroptosis is a newly found cell death mode characterized by the accumulation of reactive oxygen species (ROS), glutathione (GSH) depletion, and glutathione peroxidase 4 (GPX4) inactivation, which has been demonstrated to be beneficial to immunotherapy and combining ferroptosis and ICIs to exploit new immunotherapies may reverse ICIs resistance. Exosomes act as mediators in cell‐to‐cell communication that may regulate ferroptosis to influence immunotherapy through the secretion of biological molecules. Thus, utilizing exosomes to target ferroptosis has opened up exciting possibilities for reversing ICIs resistance. In this review, we summarize the mechanisms of ferroptosis improving ICIs therapy and how exosomes regulate ferroptosis through adjusting iron metabolism, blocking the ROS accumulation, controlling ferroptosis defense systems, and influencing classic signaling pathways and how engineered exosomes target ferroptosis and improve ICIs efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmExosomesFerroptosisImmune Checkpoint InhibitorsNeoplasmsAnimalsHumansImmunotherapyReactive Oxygen Species

Stichwörter der Autor:innen

ICIs resistanceengineered exosomesexosomesferroptosisimmunotherapy

Substanzen

Immune Checkpoint InhibitorsReactive Oxygen Species

Autor:innen und Institutionen

  • Medical College, Yangzhou University, Yangzhou, Jiangsu Province, China.
  • School of Medicine, Chongqing University, Chongqing, China.
  • Department of General Surgery, Institute of General Surgery, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China.

ORCID-Profile: Anqi Chen, Zhengting Jiang

Zitieren

APA

Chen, A., Zhang, W., Jiang, C., Jiang, Z., & Tang, D. (2024). The engineered exosomes targeting ferroptosis: A novel approach to reverse immune checkpoint inhibitors resistance. International Journal of Cancer. https://doi.org/10.1002/ijc.34934

Vancouver

Chen A, Zhang W, Jiang C, Jiang Z, Tang D. The engineered exosomes targeting ferroptosis: A novel approach to reverse immune checkpoint inhibitors resistance. International Journal of Cancer. 2024. doi:10.1002/ijc.34934

BibTeX
@article{Chen2024,
  author = {Chen, Anqi and Zhang, Wenjie and Jiang, Chuwen and Jiang, Zhengting and Tang, Dong},
  title = {The engineered exosomes targeting ferroptosis: A novel approach to reverse immune checkpoint inhibitors resistance},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34934}
}
Kostenlos starten →